To disseminate information and provide leadership related to health economics and outcomes research of precision medicine and advanced therapies.
- Establish a forum for members to engage in discussion related to the challenges of translating precision medicine and advanced therapies into clinical practice.
- Promote education related to the health economics of precision medicine and advanced therapies.
- Investigate the demonstration of value and the use of innovative payment models for precision medicine, cell therapies, gene therapies, and tissue-engineered products
The term "precision medicine" is often described as providing "the right patient with the right drug at the right dose at the right time.” More broadly, precision medicine (also known as personalized medicine) may be thought of as the tailoring of a medical treatment to the individual’s characteristics, needs, and preferences during all stages of care, including prevention, diagnosis, treatment, and follow-up. Advance therapies (also known as regenerative medicine), which include cell therapies, gene therapies, and tissue-engineered products are used in the precision medicine approach to care. These advanced therapies are often one-time treatments that are potentially curative. Together, precision medicine and advanced therapies reflect some of the most cutting-edge medical technologies available, but these therapies have unique considerations and are very different than traditional medications. The Precision Medicine and Advanced Therapies Special Interest Group seeks to explore issues related to the approval, payment, utilization, and evidence development related to the use of these technologies so they can be better used to improve the population’s health.
Melanie Whittington, MS, PhD
Molly Purser, MBA, BS, PhD
Emily Reese, PhD, MPH
- Clarissa Zerbini, BS, Global Access Strategy Leader, F.Hoffmann-La Roche Ltd, Basel, Switzerland
- Renske MT Ten Ham, MSc, PharmD, PhD, Assistant Professor HE&HTA, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
- Mona Nili, MASc, MBA, PharmD, PhD, Associate Director, Boehringer Ingelheim
Health Technology Assessment of Next Generation Diagnostic Testing Approaches
Joint project with the Medical Devices and Diagnostics Special Interest Group
- Daryl S. Spinner, PhD, MBA – Vice President, Market Access and Reimbursement, Variantyx, Inc, Greensboro, NC, United States
- Susan M. Snyder, PhD, MBA – Associate Professor, Health Policy & Behavioral Sciences, Georgia State University School of Public Health, Atlanta, GA , United States
- Bettina Zimmermann, BS, Access Global Lead, Roche, Basel, Switzerland
Manuscripts and Reports
- Zimmermann, B, Spinner, D. S, Snyder, S.R, Purser, M. Can We Demonstrate the Value of Next-Generation Sequencing Approaches Within Traditional Value Frameworks? Value and Outcomes Spotlight. 2021; 7(5)
- Faulkner, E, Holtorf, A-P, Walton, S, et al. Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group. Value in Health. 2020; 23(5):529 – 539
- Faulkner E, Annemans L, Garrison L, et al. Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health. 2012;15(8):1162-1171
- Precision Medicine and Advanced Therapies 101, Oct 23, 2019